SMAD1-AS1: A Potential Drug Target and Biomarker (G104326058)

Target Name: SMAD1-AS1

NCBI ID: G104326058

SMAD1-AS1

Other Name(s): SMAD1 antisense RNA 1

SMAD1-AS1: A Potential Drug Target and Biomarker

SMAD1-AS1 (SMAD1 antisense RNA 1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function make it an attractive target for drug development.

SMAD1-AS1 is a RNA molecule that consists of 19 non-coding nucleotides. It is derived from the protein SMAD1, which is a key regulator of gene expression and DNA replication. SMAD1 has four distinct isoforms, each with a different translation start site. SMAD1-AS1 is one of these isoforms, and it is expressed in various tissues and cells.

The function of SMAD1-AS1 is not well understood, but its involvement in gene expression regulation suggests that it plays an important role in the regulation of cellular processes. Studies have shown that SMAD1-AS1 can interact with various proteins and RNA molecules, includingribosomal RNA (rRNA), microRNA (miRNA), and double-stranded RNA (dsRNA). These interactions may regulate the translation of specific genes and contribute to the regulation of cellular processes.

SMAD1-AS1 has also been shown to play a role in the regulation of cellular signaling pathways. It has been shown to interact with various signaling proteins, including T-cell receptor (TCR),PD-L1, and NF-kappa-B. These interactions may regulate the expression of genes involved in cellular signaling pathways and contribute to the regulation of cellular processes.

In addition to its role in gene expression and cellular signaling pathways, SMAD1-AS1 has also been shown to play a role in the regulation of cellular processes related to inflammation and stress. Studies have shown that SMAD1-AS1 can interact with various pro-inflammatory molecules, including TNF-?±, IL-6, and HIF1?±. These interactions may contribute to the regulation of cellular processes related to inflammation and stress.

Given its involvement in gene expression, signaling pathways, and cellular processes related to inflammation and stress, SMAD1-AS1 may be a promising drug target and biomarker for various diseases, including cancer. Studies are currently being conducted to investigate the potential of SMAD1-AS1 as a drug target and biomarker.

One of the main challenges in the development of SMAD1-AS1 as a drug target and biomarker is its expression and function in various tissues and cells. While studies have shown that SMAD1-AS1 is expressed in various tissues and cells, its function and regulation are not well understood. Further studies are needed to clarify its function and regulation in various cellular processes.

Another challenge in the development of SMAD1-AS1 as a drug target and biomarker is its potential side effects. As with any drug, the potential side effects of SMAD1-AS1 need to be carefully evaluated before it can be used as a drug. Further studies are needed to determine the potential side effects of SMAD1-AS1 and to develop safe and effective treatments.

In conclusion, SMAD1-AS1 is a promising drug target and biomarker for various diseases, including cancer. Its unique structure and function make it an attractive target for drug development. Further studies are needed to clarify its function and regulation in various cellular processes and to evaluate its potential side effects. If its potential as a drug target and biomarker is confirmed, SMAD1-AS1 may have a significant impact on the treatment of various diseases.

Protein Name: SMAD1 Antisense RNA 1

The "SMAD1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMAD1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets